Progyny Inc. (PGNY) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, PGNY scores 78 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine (17/20): Per the RQD rating, this pillar reflects ROIC of 16.7% and an FCF yield of 8.8%. For an investor, this is the strongest pillar and suggests the business converts capital into cash efficiently relative to its market value.
• Whale 13F Flow (15/20): Institutional accumulation and options positioning. The source provides no 13F holder detail (see Analyst View section), so the score cannot be traced to specific holdings in the supplied data.
• Insider Conviction (16/20): SEC Form 4 and Congressional PTR cluster flow. The supplied holders section contains no insider transactions, so this score cannot be independently verified from the provided sources.
• Macro Regime Fit (15/20): Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level volatility relative to the broader market; an investor should weigh this against the 52-week range of $16.1 – $33.06.
• Forensic Balance Sheet (15/20): Altman Z-Score of 8.84, Piotroski F-Score of 7/9, and Debt/Equity of 0.5. These point to a financially sound balance sheet by the cited metrics.

Investor implications: The valuation tradeoff is material. At a P/E (TTM) of 37.2 and forward P/E of 34.6, the stock prices in substantial future earnings growth relative to the trailing EPS of 0.76. Upside drivers cited in the data include strong cash conversion and balance sheet metrics; the primary valuation risk is that a premium multiple leaves limited margin for execution misses. The RQD rating is a composite framework score and does not constitute a recommendation.

Progyny Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Misc Health and Biotechnology Services industry. The source data does not describe its products, customers, or specific revenue model. Per the SEC financials, the company generated FY 2025 revenue of $1288.7M, indicating scale in its reported operations.

Per the SEC financials, revenue rose from $1088.6M (FY 2023) to $1288.7M (FY 2025) and operating income rose from $62.2M to $85.3M over the same span. Per the market data, gross margin is 23.6%, operating margin 6.6%, and net margin 4.5%. Per the Roarable RQD rating, ROIC is 16.7%, and the forensic balance sheet pillar cites an Altman Z-Score of 8.84 and a Piotroski F-Score of 7/9. Cash declined from $162.3M (FY 2024) to $112.2M (FY 2025), and debt figures are not available in source data.

• Catalyst (GREEN): Yahoo Finance report "Why Are Progyny (PGNY) Shares Soaring Today," published 1h before the data timestamp, cites market action and fundamental catalysts.
• Market Wire (YELLOW): Stocktwits coverage, 3h prior, of market action and institutional positioning.
• Risk Watch (RED): Trefis piece "What Does Progyny's Falling Multiple Really Say?", 6h prior, flags multiple compression as a risk item.
• Catalyst (GREEN): ChartMill, 9h prior, references a bull flag technical setup.
• Market Wire (YELLOW): Yahoo Finance, 12h prior, notes a 56% run in the stock.
• Catalyst (GREEN): GuruFocus, 15h prior, reports a gain of 1.2 million covered lives and a 6% share rise.

The butterfly supply-chain graph reports no supply chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links recorded. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the supplied data. Investors should note that the absence of graph links means ripple effects are not quantified here. Sector context is limited to the Health Care classification and the beta of 1.0.

• What are the company's reported EPS and debt figures? The financials show EPS and debt as N/A across all periods, which prevents a direct leverage assessment.
• Why did cash decline from $162.3M to $112.2M between FY 2024 and FY 2025 despite rising FCF, and what was the use of capital?
• What drives the 37.2 trailing P/E and 34.6 forward P/E, and what earnings trajectory is assumed by the market?
• What is the source of the 13F, insider, and Congressional flow signals underlying the whale and insider pillar scores?
• What does the company actually sell and to which customers, given that the business description is not in the source data?